Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered MWX205 Injection in Adult Participants With Dyslipidemia
This study is being done to test a new injection called MWX205 in people with high cholesterol or fat levels in the blood (dyslipidemia).
Researchers will check if a single dose of MWX205 is safe and how the body reacts to it. They will also measure how quickly the drug enters the bloodstream and how long it stays in the body, and compare it with a placebo (inactive treatment).
The study will help decide the right dose and understand how this medicine could be used in future treatments.
The main questions this study aims to answer are:
- Is MWX205 safe after a single dose?
- How does the body process MWX205?
- Does MWX205 show any effect on the body related to cholesterol levels?
研究概览
详细说明
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of MWX205 Injection will be assessed in adult participants with dyslipidemia.
Overall, 37 participants will be enrolled and assigned to 5 sequential cohorts (Cohorts 1 through 5).
Cohort 1 will enroll 5 participants and be randomized 3:2 to receive a single dose of MWX205 or placebo (3 participants receiving MWX205 and 2 receiving a placebo).
Cohorts 2 to 5 will be comprised of 8 participants per Cohort and randomized 3:1 to receive a single dose of MWX205 or placebo, respectively (6 participants receiving MWX205 Injection and 2 receiving a placebo).
Dosing in each cohort will be such that 2 participants (1 MWX205 Injection and 1 placebo) will be administered at least 24 hours before the remaining 3 participants (the first cohort) or 6 participants (cohorts 2-5). After dosing the first 2 participants on a separate day, a minimum of a 5-minute dosing interval for the remaining 3 participants (the first cohort), or 6 participants (cohorts 2-5) in the following cohort, is considered acceptable.
Continuation to dose the remaining 3 participants (Cohort 1) or 6 participants (Cohorts 2-5) will be at the investigator's discretion.
Each participant will participate in 1 cohort only, residing at the Clinical Research Unit (CRU) from Day -1 (the day before dosing) to Day 8.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Mohd Naguib bin Mohd Yunos, Dr.
- 电话号码:+61 0387361750
- 邮箱:naguibyunos@veritusresearch.com
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
- Adult participants with dyslipidemia will be enrolled in this study.
- The absence of clinically significant illness and surgery within 4 weeks prior to study drug administration.
- Participants must have fasting triglycerides greater than or equal to 150 mg/dL (1.7 mmol/L) and less than 500 mg/dL (5.7 mmol/L), and LDL-C greater than or equal to 70 mg/dL (1.8 mmol/L) at pre-screening and confirmation within 7 days before randomization.
- Have a body mass index within the range 18.5 to 40.0 kg/m2 (inclusive), with no plans to significantly alter diet or BMI over the course of study.
- Females of childbearing potential and males who are not surgically sterile (> 90 days since vasectomy with no viable sperm) will agree to use contraception from Screening until 6 months after the administration, OR females of non-reproductive potential
Exclusion Criteria:
- Positive pregnancy test or lactating female participant.
- Systolic BP lower than 90 or over 140 mmHg, diastolic BP lower than 40 or over 90 mmHg, HR less than 40 or over 100 bpm at screening.
- QTcF over 450 ms at screening.
- Consume more than 7 units for women or 14 units for men of alcohol per week within 8 weeks prior to screening (1 unit = 285 mL of beer 3.5%, 75 mL of wine 13.5%, or 25 mL of distilled alcohol 40%).
- Participants with established coronary artery disease, peripheral arterial disease, prior stroke, or other clinically significant atherosclerotic cardiovascular disease (such as stent placement or heart bypass, unstable angina or last known ejection fraction of <50%).
- History of intolerance to SC injection or relevant abdominal scarring (surgical, burns, etc.), or any skin conditions, including infections or open wounds, or dermatitis at the injection site that could interfere with the evaluation of injection reaction.
- Have taken any prescription medications that are specifically indicated for lowering serum TGs (e.g., fibric acid derivatives, niacin, and omega-3 fatty acids [>1 g/day]) or medications that interfere with absorption of dietary cholesterol or fats (e.g., bile acid sequestrants, orlistat) within 2 months prior to screening.
- Have received treatment with any liver-targeted siRNA therapy or ASO (Antisense Oligonucleotide) within12 months prior to screening.
- Use of ANGPTL3 or PCSK9-inhibiting monoclonal antibodies within 90 days prior to screening.
- Use of systemic glucocorticoid therapy for more than 14 consecutive days in the past year, or any glucocorticoid therapy (excluding topical, intra-ocular, intra-articular, intranasal, or inhaled preparations) within 1 month before screening.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:MWX205
Strength: 1ml: 200 mg Proposed dose levels for SAD study: 50, 200, 400, 800, and 1200 mg Administration: subcutaneous injection, recommended in the abdomen.
|
Each vial contains 200mg of MWX205 small nucleic acid, with water for injection as the solvent.
The excipient, including sodium hydroxide and/or hydrochloric acid, may be added to adjust the pH to 6.5±0.2.
|
|
安慰剂比较:Placebo
Administration: subcutaneous injection, recommended in the abdomen.
|
匹配安慰剂
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of TEAEs
大体时间:From Day 1 to Day 86
|
From Day 1 to Day 86
|
|
|
Incidence of SAEs
大体时间:From Day 1 to Day 86
|
From Day 1 to Day 86
|
|
|
Number of participants with abnormal vital signs
大体时间:From Day 1 to Day 86
|
Vital signs include tympanic body temperature, systolic and diastolic blood pressure, pulse rate, and respiratory rate
|
From Day 1 to Day 86
|
|
Number of participants with abnormal Physical examination findings
大体时间:From Day 1 to Day 337
|
Complete physical examinations include general appearance, mouth/dental (if required), neck (including thyroid & nodes), cardiovascular, respiratory, gastrointestinal, renal, neurological, musculoskeletal, skin, other
|
From Day 1 to Day 337
|
|
Number of participants with abnormal ECG readings
大体时间:From Day 1 to Day 337
|
12 Lead ECG: Triplicate readings to be taken within 2 to 5 minutes of each other.
ECGs are to be taken after the participant has rested in the supine position for ≥ 5 minutes
|
From Day 1 to Day 337
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Plasma PK parameters Cmax (Maximum observed plasma drug concentration directly determined from the plasma concentration-time profiles)
大体时间:Day 1, Day 2, Day 3
|
Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software
|
Day 1, Day 2, Day 3
|
|
Plasma PK parameters- Tmax (Time to maximum observed plasma drug concentration)
大体时间:Day 1, Day 2, Day 3
|
Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software
|
Day 1, Day 2, Day 3
|
|
Plasma PK parameters- AUC0-inf (Area under the plasma concentration-time curve from time 0 extrapolated to infinity.)
大体时间:Day 1, Day 2, Day 3
|
Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software
|
Day 1, Day 2, Day 3
|
|
Plasma PK parameters- AUC0-last (Area under the plasma concentration-time curve, from time zero to the last time point with measurable analyte concentration)
大体时间:Day 1, Day 2, Day 3
|
Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software
|
Day 1, Day 2, Day 3
|
|
Urine PK parameters- Fe (dose fraction of the drug in its original form excreted in urine after administration)
大体时间:Day 1, Day 2, Day 3
|
Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software
|
Day 1, Day 2, Day 3
|
|
Urine PK parameters- Ae (cumulative excretion of the drug's original form in urine)
大体时间:Day 1, Day 2, Day 3
|
Non-compartmental analysis (NCA) will be used to calculate the PK parameters with Phoenix WinNonlin Software
|
Day 1, Day 2, Day 3
|
合作者和调查者
调查人员
- 首席研究员:Mohd Naguib bin Mohd Yunos, Dr.、Veritus Research
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.